Home › NDC Lookup › Ingredients › Poa Pratensis › 22840-0202-04
Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution, 50 mL — NDC 22840-0202-04 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution, 50 mL — NDC 22840-0202-4 (Billing 22840-0202-04)

by Greer Laboratories, Inc. · 50 mL in 1 VIAL, MULTI-DOSE

This is a package of 50 mL of Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution from Greer Laboratories, Inc., first listed with the FDA Sep 1968 and currently FDA-listed.

NDC 22840-0202-04
🏷️ FDA NDC (as labeled) 22840-0202-4 billing pads the package segment with a zero
This package
Contains50 mL Pack sizes3 compare ↓
Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Oct 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 22840-0202-4 alone.

Record
FDA NDC Directory package listing · Standardized allergenic
Code segments
22840 labeler · 0202 product · 4 package
Package marketed since
Sep 15, 1968
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 2284002024 7
FDA record last changed
Oct 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 22840-0202-4
Product NDC 22840-0202
11-digit billing NDC 22840020204
Application # BLA101837
SPL Set ID 60b8218f-84f0-1acc-e053-2991aa0a2795
Established class (EPC) Standardized Pollen Allergenic Extract
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Pollen
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 1968-09-15
Route INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS
Dosage form SOLUTION
Substance POA PRATENSIS POLLEN
Biologic (Purple Book) 351(a)
Why two NDCs? The FDA registers this code as 22840-0202-4 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 22840-0202-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 5 ml 10 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
22840-0202-02 22840-0202-2 Main listing 10 mL in 1 VIAL, MULTI-DOSE 1968-09-15 — Active
22840-0202-04 You're viewing this 50 mL in 1 VIAL, MULTI-DOSE 1968-09-15 — Active
22840-0202-05 22840-0202-5 5 mL in 1 BOTTLE, DROPPER 1968-09-15 — Active

You're viewing the largest of 3 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 50 mL — 50 ml in 1 vial, multi-dose.
How does this package differ from NDC 22840-0202-05?
Both are Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution — the drug itself is identical. This page's package is the 50 mL one, while NDC 22840-0202-05 is the 5 ml package.
What NDC number is used to bill for this package of Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Kentucky Bluegrass (June) Standardized 100000 [BAU]/mL 00268-0283-10 ALK-Abello, 10 ml — — FDA listed —
Kentucky Bluegrass (June) Standardized 100000 [BAU]/mL 00268-3051-06 ALK-Abello, 5 ml — — FDA listed —
Standardized Kentucky (June) Bluegrass Pollen 100000 [BAU]/mLthis 22840-0202-04 Greer 50 ml — — FDA listed —
Standardized Kentucky Blue (June) Grass 100000 [BAU]/mL 49643-0393-05 Allermed 5 ml — — FDA listed —
Standardized Grass Pollen, Bluegrass, Kentucky June 100000 [BAU]/mL 65044-0546-01 Jubilant 5 ml — — Discontinued —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1930
First FDA approval
Jun 1930
📍
2026
Currently FDA-listed
96 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 339NCG44TV
    Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
  • UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerGreer Laboratories, Inc.
FDA applicationBLA101837 (BLA)
Labeler code22840
First marketedSep 1968
Product typeStandardized Allergenic
Portfolio1,328 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 175 words ▾

FULL PRESCRIBING INFORMATION WARNING: SEVERE ALLERGIC REACTIONS Standardized Grass Pollen Allergenic Extracts can cause severe life-threatening systemic reactions, including anaphylaxis. (5.1) Do not administer Standardized Grass Pollen Allergenic Extracts to patients with severe, unstable, or uncontrolled asthma. (4) Observe patients in the office for at least 30 minutes following treatment.Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction.

(5.1) Patients with extreme sensitivity, to Standardized Grass Pollen Allergenic Extracts, those on an accelerated immunotherapy build-up schedule, those switching to another allergenic lot, those receiving high doses of the Standardized Grass Pollen Allergenic Extracts, or those also exposed to similar allergens may be at increased risk of a severe allergic reaction. (5.1) Standardized Grass Pollen Allergenic Extracts may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.

(5.1) Standardized Grass Pollen Allergenic Extracts may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta‑blockers. (5.2)

🎯 Indications and Usage 100 words ▾

1 INDICATIONS AND USAGE GREER Standardized Grass Pollen Allergenic Extracts are indicated for: Skin test diagnosis of patients with a clinical history of allergy to one or more of the following grass pollens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, Timothy. Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies for Bermuda grass pollen, Kentucky Blue (June) grass pollen, Meadow Fescue grass pollen, Orchard grass pollen, Perennial Rye grass pollen, Redtop grass pollen, Sweet Vernal grass pollen, or Timothy grass pollen.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION For percutaneous, intradermal or subcutaneous use only. The extracts are diluted with sterile diluents when used for intradermal testing or subcutaneous immunotherapy. For percutaneous testing, the extracts are diluted with sterile diluents in patients expected to be at greater risk for systemic allergic reaction. Dosages vary by mode of administration and by individual response.

2.1Preparation for Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard solution if either of these conditions exist. The extracts are diluted with sterile diluents when used for percutaneous and intradermal testing, or for subcutaneous immunotherapy.

Undiluted 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrates are used for percutaneous testing. To prepare 10-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate. Proceed as shown in Table 1.

The 10-fold dilution series uses 0.5 milliliters of concentrate added to 4.5 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 10-fold dilutions for intradermal testing and immunotherapy, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate.

Proceed as shown in Table 1. The 10-fold dilution series uses 0.5 milliliters of concentrate added to 4.5 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.

Table 1: 10-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution Strength (BAU/mL) Dilution Strength (BAU/mL 0 Concentrate 100,000 10,000 1 0.5 mL Concentrate 4.5 10,000 1,000 2 0.5 mL Dilution 1 4.5 1,000 100 3 0.5 mL Dilution 2 4.5 100 10 4 0.5 mL Dilution 3 4.5 10 1 5 0.5 mL Dilution 4 4.5 1 0.1 6 0.5 mL Dilution 5 4.5 0.1

0.01Undiluted 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrates are used for percutaneous testing. To prepare 5-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate. Proceed as shown in Table 2.

The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 5-fold dilutions for intradermal testing and immunotherapy, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate.

Proceed as shown in Table 2. The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.

Table 2: 5-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution Strength (BAU/mL) Dilution Strength (BAU/mL) 0 Concentrate 100,000 10,000 1 1 mL Concentrate 4 20,000 2,000 2 1 mL Dilution 1 4 4,000 400 3 1 mL Dilution 2 4 800 80 4 1 mL Dilution 3 4 160 16 5 1 mL Dilution 4 4 32 3.2 6 1 mL Dilution 5 4 6.4 0.64

2.2Diagnostic Testing Diagnostic testing can be performed via percutaneous or intradermal administration of the Standardized Grass Pollen Allergenic Extracts. A positive skin test reaction should be interpreted in relation to the patient’s history and known exposure to the allergen. If a skin test with a grass pollen extract mixture elicits a positive reaction, then the single-species grass pollen extracts can be used to determine the degree of sensitivity to each individual grass species and to guide in the selection of extracts and their concentration for immunotherapy, i… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 38 words ▾

3 DOSAGE FORMS AND STRENGTHS Standardized Bermuda Grass Pollen Allergenic Extract solution is available only at 10,000 Bioequivalent Allergy Units (BAU)/milliliter. Other Standardized Grass Pollen Allergenic Extract solutions are available as stock concentrates at 10,000 and 100,000 BAU/milliliter.

⛔ Contraindications 33 words ▾

4 CONTRAINDICATIONS Standardized Grass Pollen Allergenic Extracts are contraindicated in patients with: Severe, unstable or uncontrolled asthma History of any severe systemic allergic reaction or any severe local reaction to subcutaneous allergen immunotherapy

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS

5.1Serious Systemic Adverse Reactions Serious systemic adverse reactions have occurred following the administration of other allergenic extracts and may occur in individuals following the administration of Standardized Grass Pollen Allergenic Extracts in the following situations: Extreme sensitivity to grass pollen allergenic extracts Receipt of an accelerated immunotherapy build-up schedule (e.g., “rush” immunotherapy) Receipt of high doses of grass pollen allergenic extracts or concomitant exposure to similar environmental allergens Change from one allergenic lot to another allergenic lot High-risk patients have had fatal reactions.

Consider using more dilute preparations in patients suspected to be at greater risk of systemic allergic reaction [see Dosage and Administration (2.1)]. Administer Standardized Grass Pollen Allergenic Extracts in a healthcare setting under the supervision of a physician prepared to manage a severe systemic or a severe local allergic reaction. Observe patients in the office for at least 30 minutes following administration.

1

5.2Epinephrine Standardized Grass Pollen Allergenic Extracts may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. These products may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine.

These medications include: Βeta-adrenergic blockers : Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine. Alpha-adrenergic blockers, ergot alkaloids : Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis.

Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine. Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and certain antihistamines : The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.

Cardiac glycosides, diuretics : Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.

5.3Cross-Reactions and Dose Sensitivity Since many grass species tend to cross-react, the total allergen content should be considered in determining the maximum maintenance dose of the mixture. Determine the initial dilution of allergenic extract, starting dose, and progression of dosage based on the patient’s history and results of skin tests [see Dosage and Administration (2.2)]. 2 Strongly positive skin tests can be indicators for potential systemic reactions.

🤒 Adverse Reactions 68 words ▾

6 ADVERSE REACTIONS The most common adverse reactions, occurring in 26 to 82% of all patients who receive subcutaneous immunotherapy are local adverse reactions at the injection site (e.g., erythema, itching, swelling, tenderness, pain). 1 Systemic adverse reactions, occurring in 7% of patients who receive subcutaneous immunotherapy, 3 include generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. These adverse reactions can be fatal.

1

🔄 Drug Interactions 127 words ▾

7 DRUG INTERACTIONS

7.1Antihistamines Do not perform skin testing with allergenic extracts within 3 to 10 days of use of first-generation H 1 -histamine receptor blockers (e.g., clemastine, diphenhydramine) and second-generation antihistamines (e.g., loratadine, cetirizine). These products suppress histamine skin test reactions and could mask a positive response. 2

7.2Topical Corticosteroids and Topical Anesthetics Topical corticosteroids can suppress skin reactivity; therefore, discontinue use at the skin test site for 2 to 3 weeks before skin testing. Avoid use of topical local anesthetics at skin test sites as they can suppress flare responses. 2

7.3Tricyclic Antidepressants Tricyclic antidepressants can have potent antihistamine effects that can affect skin testing. If tricyclic medication has been recently discontinued, allow 7 to 14 days before initiating skin testing. 2

👥 Use in Specific Populations 220 words ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Allergenic Extracts-associated risks during pregnancy.

8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Allergenic Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Allergenic Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.

8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patients’ ability to comply and cooperate with allergen immunotherapy and the potential for difficulty in communicating with the child regarding systemic reactions. 1

8.5Geriatric Use Data are not available to determine if subjects 65 years of age and older respond differently to allergen immunotherapy than younger subjects.

🧬 Clinical Pharmacology 79 words ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The skin test reaction results from interaction of the introduced allergen and allergen-specific IgE antibodies bound to mast cells, leading to mast cell degranulation and release of histamine, tryptase and other mediators, which results in the formation of the wheal and flare. The precise mechanisms of action of allergen immunotherapy are not known. Immunologic responses to immunotherapy include changes in allergen-specific IgE levels, allergen-specific IgG levels, and regulatory T cell responses.

1

📦 How Supplied / Storage and Handling ~2 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied GREER Standardized Grass Pollen Allergenic Extracts and mixes are supplied as stock concentrates at 10,000 BAU/milliliter and 100,000 BAU/milliliter in 50% glycerin for use in percutaneous skin testing, intradermal testing, and subcutaneous immunotherapy. Standardized Grass Pollen Allergenic Extracts are labeled in BAU/milliliter and are provided in 5, 10, and 50 milliliter vials. Note, the total potency of mixes containing standardized grasses may be cumulative.

Standardized Bermuda Grass Pollen Allergenic Extract solution is available only at 10,000 BAU/milliliter. GREER Standardized Grass Pollen Allergenic Extracts and mixes are supplied as follows: Standardized Bermuda Grass Pollen (Cynodon dactylon) NDC Number Strength/Container 22840-0200-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0200-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0200-4 10,000 BAU/mL, 50 mL multiple-dose vials Standardized Bluegrass, Kentucky (June) Grass Pollen (Poa pratensis) NDC Number Strength/Container 22840-0201-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0201-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0201-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0202-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0202-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0202-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Meadow Fescue Grass Pollen (Festcua elatoir) NDC Number Strength/Container 22840-0203-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0203-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0203-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0204-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0204-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0204-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Orchard Grass Pollen (Dactylis glomerata) NDC Number Strength/Container 22840-0205-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0205-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0205-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0206-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0206-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0206-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Perennial Rye Grass Pollen (Lolium perenne) NDC Number Strength/Container 22840-0209-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0209-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0209-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0210-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0210-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0210-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Redtop Grass Pollen (Agrostis alba) NDC Number Strength/Container 22840-0207-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0207-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0207-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0208-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0208-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0208-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Sweet Vernal Grass Pollen (Anthoxanthum odoratum) NDC Number Strength/Container 22840-0211-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0211-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0211-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0212-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0212-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0212-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Timothy Grass Pollen (Phelum pratense) NDC Number Strength/Container 22840-0213-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0213-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0213-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0214-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin)… [Excerpted — this section continues on DailyMed.]

📋 Description ~1 min read ▾

11 DESCRIPTION Standardized Grass Pollen Allergenic Extracts include Standardized Bermuda Grass Pollen ( Cynodon dactylon ) at 10,000 BAU/milliliter, 50% glycerin volume/volume, and 0.4% phenol (preservative); and the following grasses at both 10,000 BAU/milliliter and 100,000 BAU/milliliter, 50% glycerin volume/volume, and 0.4% phenol: Standardized Kentucky Blue (June) Grass Pollen ( Poa pratensis ), Standardized Meadow Fescue Grass Pollen ( Festuca elatior ), Standardized Orchard Grass Pollen ( Dactylis glomerata ), Standardized Perennial Rye Grass Pollen ( Lolium perenne ), Standardized Redtop Grass Pollen ( Agrostis alba ), Standardized Sweet Vernal Grass Pollen ( Anthoxanthum odoratum ), and Standardized Timothy Grass Pollen ( Phleum pratense ).

Inactive ingredients include 0.25% sodium chloride for isotonicity and 0.25% sodium bicarbonate as a buffer. Standardized Grass Pollen Allergenic Extracts should be clear light yellow to brownish solutions that are free of particulate matter. Standardized Grass Pollen Allergenic Extracts are labeled in BAU/milliliter.

Bioequivalent Allergy Units are assigned based on comparison by enzyme-linked immunosorbent assay (ELISA) to references from the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). CBER references are assigned unitage based on quantitative skin testing.

4,5,6,7 CBER references which can be diluted 1:5,000,000 to intradermally elicit a 50 millimeter sum of erythema diameter response in highly puncture reactive subjects are assigned 100,000 BAU/milliliter; whereas references diluted 1:500,000 which elicit the same 50 millimeter sum of erythema diameter response are assigned 10,000 BAU/milliliter.

🔬 Clinical Studies 46 words ▾

14 CLINICAL STUDIES Specific immunotherapy with pollen extracts is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S. Food and Drug Administration, has been published. 8

📚 References ~1 min read ▾

15 REFERENCES Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol .

2011:S1-S55. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter.

Ann Allergy Asthma Immunol . 2008;100:S1-148. Greenberg MA, Kaufman CR, Gonzalez GE, et al.

Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol . 1986;77:865-870.

Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol .

1982; 70:343-352. ELISA competition assay. Methods of the Allergenic Products Testing Laboratory.

Rockville, MD: Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology, Center for Biologics Evaluation and Research, Food and Drug Administration; October 1993. (On file) Turkeltaub PC, Rastogi SC. Quantitative intradermal procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of bioequivalent allergy units to reference preparations using the ID50EAL method.

Rockville, MD: Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology, Center for Biologics Evaluation and Research, Food and Drug Administration; November 1994. (On file) Turkeltaub PC. Assignment of bioequivalent allergy units based on biological standardization methods.

Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M . 1988;(82):19-40. Implementation of Efficacy Review, Allergenic Extracts, Federal Register 1985; 50: 3082-3288.

📄 Package Label / Principal Display Panel 41 words ▾

0200-4_Bermuda_10000-bau 0201-2_Kentucky_Blue_June_10000-bau 0202-5_Kentucky_Blue_June_100000-bau 0203-2_Meadow_Fescue_10000-bau 0204-4_Meadow_Fescue_100000-bau 0205-5_Orchard_10000-bau 0206-2_Orchard_100000-bau 0207-4_Redtop_10000-bau 0208-2_Redtop_100000-bau 0209-5_Perennial_Rye_10000-bau 0210-4_Perennial_Rye_Grass_100000-bau 0211-5_Sweet_Vernal_10000-bau 0212-4_Sweet_Vernal_Grass_100000-bau 0213-2_Timothy_10000-bau 0214-4_Timothy_100000-bau 0215-5_Timothy-Orchard_Grass_100000-bau 0216-2_KOT_Grass_10000-bau 0217-4_KOT_Grass_100000-bau 0218-5_KORT_Grass_10000-bau 0219-2_KORT_Grass_100000-bau 0220-4_KORT-SV_Grass_10000-bau 0221-2_KORT-SV_Grass_100000-bau 0222-5_7_Grass_10000-bau 0223-4_7_Grass_100000-bau 0224-5_TOS Grass_10000-bau 0226-2_Timothy-Orchard_Grass_10000-bau 0227-5_TOS Grass_100000-bau 0225-2_9 Southern Grass Mix_Conc 0225-4_9 Southern Grass Mix_Conc 0225-5_9 Southern Grass Mix_Conc

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Poa pratensis — the ingredient across all brands.

Top reported reactions

Wheezing3
Cough2
Dyspnoea2
Flushing2
Rhinorrhoea2
Anaphylactic Reaction1
Blood Pressure Decreased1

Reporter sex

6 reports
Male · 67%
Female · 33%
Reports over time (by year) — tap or hover for the count & year
2023 2024 2025 2026 2 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Greer Laboratories, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 5 ml (22840-0202-05), 10 ml (22840-0202-02). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Greer Laboratories, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.